ࡱ> yx \p ktzovelekis Ba=  =xKx<$8X@"1&Arial1&Arial1&Arial1&Arial1&Arial1&Verdana1&Arial1 &Arial1$&Arial"$"#,##0_);\("$"#,##0\)!"$"#,##0_);[Red]\("$"#,##0\)""$"#,##0.00_);\("$"#,##0.00\)'""$"#,##0.00_);[Red]\("$"#,##0.00\)7*2_("$"* #,##0_);_("$"* \(#,##0\);_("$"* "-"_);_(@_).))_(* #,##0_);_(* \(#,##0\);_(* "-"_);_(@_)?,:_("$"* #,##0.00_);_("$"* \(#,##0.00\);_("$"* "-"??_);_(@_)6+1_(* #,##0.00_);_(* \(#,##0.00\);_(* "-"??_);_(@_)3#,##0\ " ";\-#,##0\ " "=#,##0\ " ";[Red]\-#,##0\ " "?#,##0.00\ " ";\-#,##0.00\ " "I"#,##0.00\ " ";[Red]\-#,##0.00\ " "q6_-* #,##0\ " "_-;\-* #,##0\ " "_-;_-* "-"\ " "_-;_-@_-k3_-* #,##0\ _ _-;\-* #,##0\ _ _-;_-* "-"\ _ _-;_-@_->_-* #,##0.00\ " "_-;\-* #,##0.00\ " "_-;_-* "-"??\ " "_-;_-@_-{;_-* #,##0.00\ _ _-;\-* #,##0.00\ _ _-;_-* "-"??\ _ _-;_-@_-![$-408]dddd\,\ d\ mmmm\ yyyy"Yes";"Yes";"No""True";"True";"False""On";"On";"Off"],[$ -2]\ #,##0.00_);[Red]\([$ -2]\ #,##0.00\)                         "x@ @  "X    p Q  Q Q   `&DrugDevelopmentAug2008".DrugDevelopmentSept20085DrugDevelopmentOct08=DrugDevelopmentNov08 EDrugDevelopmentDec08!Laboratory products Aug08$#Laboratory products Sept2008!Laboratory products Oct08!Laboratory products Nov08!Laboratory products Dec08"<TDateURLTitleSummarySourceNameCompany DescriptionUSchering-Plough's selective relaxant binding agent Bridion injection gets EC approvalSchering-Plough Corporation announced that the European Commission (EC) has approved Bridion (sugammadex) injection, the first and only Selective Relaxant Binding Agent PharmaBizPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45451§ionid=14Amgen has licensed a clinical stage molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc (OMJPI), a Johnson & Johnson company4Amgen licenses pain molecule to Ortho-McNeil-JanssenPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45487§ionid=43-Mayo Clinic initiates phase-1b study of CD-NPNile Therapeutics, Inc announced that Mayo Clinic has initiated a phase-1b, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in developmentOhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45520§ionid=4?Pro- Pharma gets US FDA nod for Davanat combo for breast cancer pharmaBizPro-Pharmaceuticals, Inc announced that the U S Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patientPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45896§ionid=148Protherics starts Prolarix phase-2 study in liver cancerProtherics PLC , the international biopharmaceutical company focused on critical care and cancer, announced the initiation of a phase-2a proof-of-concept study of Prolarix, which is a targeted prodrug chemotherapy being developedOhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45897§ionid=4\ImClone starts patient enrolment in phase 2 study of IMC-A12 & IMC-1121B for prostate cancerImClone Systems Incorporated, a global leader in the development and commercialization of novel antibodies to treat cancer, announced that its disease-directed phase-2 clinical trial in patients with advanced prostate cancerOhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45916§ionid=4UDSMB recommends continuation of phase-III trial of Iluvien for diabetic macular edemaGlobal drug delivery company, pSivida Corp announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB)Ohttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46359§ionid=4=Takeda seeks Alogliptin approval in Japan for type-2 diabetesTakeda Pharmaceutical Company Limited has filed a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare for Alogliptin (development code: SYR-322) for treatment of type-2 diabetesPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46353§ionid=43@ONI BioPharma licenses unique gene targets for colorectal cancerONI BioPharma Inc has entered a collaboration agreement with a major international diagnostics company regarding ONI's unique biomarkers for early, middle and late stage colorectal cancerOhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46388§ionid=3IUS FDA grants nod for 75th generic anti-retroviral drug as part of PEPFARThe Food and Drug Administration within the US Department of Health and Human Services (HHS) has reached the milestone of the 75th anti-retroviral generic drug PharmabizPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46767§ionid=145US FDA approves new indication for Hospira's PrecedexHospira, Inc, a global specialty pharmaceutical and medication delivery company, announced that the US Food and Drug Administration (FDA)Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46784§ionid=14PBiocon's oncology, rheumatoid arthritis and psoriasis drugs under phase-II studypBiocon is evaluating the safety and efficacy of its three drugs for oncology, rheumatoid arthritis and psoriasisOhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46775§ionid=4IWyeth, Progenics report positive results from phase III study of RelistorsWyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals, Inc. said their phase III clinical studyOhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47201§ionid=4BRoche to address unmet need in rheumatology arthritis with ActemraRoche Pharmaceuticals is all set to address the unmet need in rheumatology by developing therapies that help patients achieve the ultimate goal of remission*-;Merck's Erbitux receives EC approval for head & neck cancerPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47237§ionid=14Ohttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47245§ionid=6Merck KGaA and its Merck Serono division announced that it has received approval from the European Commission to extend the use of its targeted therapy Erbitux (cetuximab) to include first-line treatment of patients&CONTROL SLIDE, CD20 (B-CELL)[L26],5-PKBioGenexWhttp://www.biocompare.com/ProductDetails/350821/CONTROL-SLIDE,-CD20-B-CELLL26,5-PK.html+ TONSIL. Control slides CONTROL SLIDE, CD43(B CELL)[LN2]Vhttp://www.biocompare.com/ProductDetails/351062/CONTROL-SLIDE,-CD43B-CELLLN2,5-PK.htmlCONTROL SLIDE, B CDELL[MB2]Shttp://www.biocompare.com/ProductDetails/351061/CONTROL-SLIDE,-B-CDELLMB2,5-PK.html CONTROL SLIDE, MAST CELL TRYPTSE[http://www.biocompare.com/ProductDetails/351060/CONTROL-SLIDE,-MAST-CELL-TRYPTSE,-5-PK.html pORF-hIL10R-A InvivogengHuman IL10R-A ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with AmpicillinBhttp://www.biocompare.com/ProductDetails/392043/pORF-hIL10R-A.html pORF-hIL10R-BgHuman IL10R-B ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with AmpicillinBhttp://www.biocompare.com/ProductDetails/392044/pORF-hIL10R-B.htmlpORF-hIL13R-A1(s){Human IL13R-A1 (soluble receptor) ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with AmpicillinDhttp://www.biocompare.com/ProductDetails/392045/pORF-hIL13R-A1s.htmlpORF-hIL13R-A2(s){Human IL13R-A2 (soluble receptor) ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with AmpicillinDhttp://www.biocompare.com/ProductDetails/392046/pORF-hIL13R-A2s.html pORF-hIL-17RfHuman IL-17R ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with AmpicillinAhttp://www.biocompare.com/ProductDetails/392047/pORF-hIL-17R.htmlZ$ k S:"u]  @(k!S+#U%=cc  '_)  dMbP?_*+%"??U} m} } } } m      ~ C@     ~ G@    ~ @O@    h<FFF>@  7|yK Qhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45451&sectionid=14yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45451&sectionid=14|yK Qhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45487&sectionid=43yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45487&sectionid=43xyK Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45520&sectionid=4yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45520&sectionid=4   .0  dMbP?_*+%"F??PU} $ F} $ F        ~ D@    ~ D@    ~ G@      D xFFFF>@7|yK Qhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45896&sectionid=14yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45896&sectionid=14xyK Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45897&sectionid=4yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45897&sectionid=4xyK Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45916&sectionid=4yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45916&sectionid=4  ,688  dMbP?_*+%"F??PU} $ F} $ F,      ~  D@    ~  D@   ! "~ O@  # $   FFFF + +">@7xyK Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46359&sectionid=4yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46359&sectionid=4|yK Qhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46353&sectionid=43yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46353&sectionid=43xyK Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46388&sectionid=3yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46388&sectionid=3  \>D@  dMbP?_*+%"F??PU} $ F} $ F@@@@@      %~ @D@ ' & ( )~ @D@ ' * + ,~ K@ ' - .  dFFFF>@7|yK Qhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46767&sectionid=14yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46767&sectionid=14|yK Qhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46784&sectionid=14yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46784&sectionid=14xyK Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46775&sectionid=4yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46775&sectionid=4   egggggghhhh'h/h7h?hGhOhWh_hghohwhhhhhhhhhhhhhhhhhhiiii'i/i7i?iGiOiWi_igioiwiiiiiiiiiiiiiiiiiijjjj'j/j7j?jGjOjWj_jgjojwjjjjjjjjjjjjjjjjjjkkkk'k/k7k?kGkOkWk_kgkokwkkkkkkkkkkkkkkkkkkllll'l/l7l?lGlOlWl_lglolwllllllllllllllllllmmmm'm/m7m?mGmOmWm_mgmomwmmmmmmmmmmmmmmmmmmnnnn'n/n7n?nGnOnWn_ngnonwnnnnnnnnnnnnnnnnnnoooo'o/o7o?oGoOoWo_ogooowoooooooooooooooooopppp'p/p7p?pGpOpWp_pgpopwppppppppppppppppppqqqq'q/q7q?qGqOqWq_qgqoqwqqqqqqqqqqqqqqqqqqrrrr'r/r7r?rGrOrWr_rgrorwrrrrrrrrrrrrrrrrrrssss's/s7s?sGsOsWs_sgsoswsssssssssssssssssstttt't/t7t?tGtOtWt_tgtotwttttttttttttttttttuuuu'u/u7u?uGuOuWu_uguouwuuuuuuuuuuuuuuuuuuvvvv'v/v7v?vGvOvWv_vgvovwvvvvvvvvvvvvvvvvvvwwww'w/w7w?wGwOwWw_wgwowwwwwwwwwwwwwwwwwwwwxxxx'x/x7x?xGxOxWx_xgxoxwxxxxxxxxxxxxxxxxxxyyyy'y/y7y?yGyOyWy_ygyoywyyyyyyyyyyyyyyyyyyzzzz'z/z7z?zGzOzWz_zgzozwzzzzzzzzzzzzzzzzzz{{{{'{/{7{?{G{O{W{_{g{o{w{{{{{{{{{{{{{{{{{{||||'|/|7|?|G|O|W|_|g|o|w||||||||||||||||||}}}}'}/}7}?}G}O}W}_}g}o}w}}}}}}}}}}}}}}}}}}~~~~'~/~7~?~G~O~W~_~g~o~w~~~~~~~~~~~~~~~~~~'/7?GOW_gow'/7?GOW_gowǀπ׀߀'/7?GOW_gowǁρׁ߁'/7?GOW_gowǂςׂ߂'/7?GOW_gowǃσ׃߃'/7?GOW_gowDŽτׄ߄'/7?GOW_gowDžυׅ߅'/7?GOW_gowdžφ׆߆'/7?GOW_gowLJχׇ߇'/7?GOW_gowLjψ׈߈'/7?GOW_gowljω׉߉'/7?GOW_gowNJϊ׊ߊ'/7?GOW_gowNjϋ׋ߋ'/7?GOW_gownjό׌ߌ'/7?GOW_gowǍύ׍ߍ'/7?GOW_gowǎώ׎ߎ'/7?GOW_gowǏϏ׏ߏ'/7?GOW_gowǐϐאߐ'/7?GOW_gowǑϑבߑ'/7?GOW_gowǒϒגߒ'/7?GOW_gowǓϓדߓ'/7?GOW_gowǔϔהߔ'/7?GOW_gowǕϕוߕ'/7?GOW_gowǖϖזߖ'/7?GOW_gowǗϗחߗ'/7?GOW_gowǘϘטߘ'/7?GOW_gowǙϙיߙ'/7?GOW_gowǚϚךߚ'/7?GOW_gowǛϛכߛ'/7?GOW_gowǜϜלߜ'/7?GOW_gowǝϝםߝ'/7?GOW_gowǞϞמߞ'/7?GOW_gowǟϟןߟ'/7?GOW_gowǠϠנߠ'/7?GOW_gowǡϡסߡ'/7?GOW_gowǢϢעߢ'/7?GOW_gowǣϣףߣ'/7?GOW_gowǤϤפߤ'/7?GOW_gowǥϥץߥ'/7?GOW_gowǦϦצߦ'/7?GOW_gowǧ  dMbP?_*+%"F??PU} $ F} $ F      /~ `D@ ' 0 1 2~ `D@ ' 3 7 5~ `D@ ' 8 6  xFFFF 4">@  7xyK Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47201&sectionid=4yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47201&sectionid=4|yK Qhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47237&sectionid=14yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47237&sectionid=14xyK Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47245&sectionid=6yK http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47245&sectionid=6  f  dMbP?_*+%"F??PU} m%F} $ F} F     9 : = ; Q E R S   <Jd888>@  7yK Xhttp://www.biocompare.com/ProductDetails/350821/CONTROL-SLIDE,-CD20-B-CELLL26,5-PK.htmlyK http://www.biocompare.com/ProductDetails/350821/CONTROL-SLIDE,-CD20-B-CELLL26,5-PK.html@yK Bhttp://www.biocompare.com/ProductDetails/392047/pORF-hIL-17R.htmlyK http://www.biocompare.com/ProductDetails/392047/pORF-hIL-17R.html  ߲Q  dMbP?_*+%"F??BU} m%F} $ F} F     > : = ? N E O P  *P888>@  7yK Whttp://www.biocompare.com/ProductDetails/351062/CONTROL-SLIDE,-CD43B-CELLLN2,5-PK.htmlyK http://www.biocompare.com/ProductDetails/351062/CONTROL-SLIDE,-CD43B-CELLLN2,5-PK.htmlLyK Ehttp://www.biocompare.com/ProductDetails/392046/pORF-hIL13R-A2s.htmlyK http://www.biocompare.com/ProductDetails/392046/pORF-hIL13R-A2s.html  >x  dMbP?_*+%"F??EU} $F} $F     @ : = A K E L M <888>@  7yK Thttp://www.biocompare.com/ProductDetails/351061/CONTROL-SLIDE,-B-CDELLMB2,5-PK.htmlyK http://www.biocompare.com/ProductDetails/351061/CONTROL-SLIDE,-B-CDELLMB2,5-PK.htmlLyK Ehttp://www.biocompare.com/ProductDetails/392045/pORF-hIL13R-A1s.htmlyK http://www.biocompare.com/ProductDetails/392045/pORF-hIL13R-A1s.html  Ws  dMbP?_*+%"F??EU} $F} $F     B : = C H E I J (88>@  7yK \http://www.biocompare.com/ProductDetails/351060/CONTROL-SLIDE,-MAST-CELL-TRYPTSE,-5-PK.htmlyK http://www.biocompare.com/ProductDetails/351060/CONTROL-SLIDE,-MAST-CELL-TRYPTSE,-5-PK.htmlDyK Chttp://www.biocompare.com/ProductDetails/392044/pORF-hIL10R-B.htmlyK http://www.biocompare.com/ProductDetails/392044/pORF-hIL10R-B.html  h  dMbP?_*+%"F??CU} $F} $F     @ : = A D E F G (88>@  7yK Thttp://www.biocompare.com/ProductDetails/351061/CONTROL-SLIDE,-B-CDELLMB2,5-PK.htmlyK http://www.biocompare.com/ProductDetails/351061/CONTROL-SLIDE,-B-CDELLMB2,5-PK.htmlDyK Chttp://www.biocompare.com/ProductDetails/392043/pORF-hIL10R-A.htmlyK http://www.biocompare.com/ProductDetails/392043/pORF-hIL10R-A.html Oh+'0h08 H T`Ourania@cZ@ v]r՜.+,D՜.+,HP X`hp x   DrugDevelopmentAug2008DrugDevelopmentSept2008DrugDevelopmentOct08DrugDevelopmentNov08DrugDevelopmentDec08Laboratory products Aug08Laboratory products Sept2008Laboratory products Oct08Laboratory products Nov08Laboratory products Dec08  Worksheets  8@ _PID_HLINKSA$tPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45520&sectionid=4MQhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45487&sectionid=43GQhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45451&sectionid=14.wPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45916&sectionid=4.Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45897&sectionid=4KQhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=45896&sectionid=14*}Phttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46388&sectionid=3CQhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46353&sectionid=43+pPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46359&sectionid=4#rPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46775&sectionid=4IQhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46784&sectionid=14GQhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=46767&sectionid=14&pPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47245&sectionid=6CQhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47237&sectionid=14"tPhttp://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=47201&sectionid=4\ Bhttp://www.biocompare.com/ProductDetails/392047/pORF-hIL-17R.htmle<Xhttp://www.biocompare.com/ProductDetails/350821/CONTROL-SLIDE,-CD20-B-CELLL26,5-PK.htmlIWEhttp://www.biocompare.com/ProductDetails/392046/pORF-hIL13R-A2s.html`+Whttp://www.biocompare.com/ProductDetails/351062/CONTROL-SLIDE,-CD43B-CELLLN2,5-PK.htmlJTEhttp://www.biocompare.com/ProductDetails/392045/pORF-hIL13R-A1s.htmlt9Thttp://www.biocompare.com/ProductDetails/351061/CONTROL-SLIDE,-B-CDELLMB2,5-PK.html;fChttp://www.biocompare.com/ProductDetails/392044/pORF-hIL10R-B.htmlet\http://www.biocompare.com/ProductDetails/351060/CONTROL-SLIDE,-MAST-CELL-TRYPTSE,-5-PK.html?f Chttp://www.biocompare.com/ProductDetails/392043/pORF-hIL10R-A.htmlt9 Thttp://www.biocompare.com/ProductDetails/351061/CONTROL-SLIDE,-B-CDELLMB2,5-PK.html  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcefghijkmnopqrstuvwRoot Entry FPv8.vWorkbookSummaryInformation(dDocumentSummaryInformation8l